NOVKAN — Novakand Pharma AB Share Price
- SEK27.75m
- SEK0.20m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.64 | ||
Price to Tang. Book | 1.1 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -94.77% | ||
Return on Equity | -63.24% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | SEKm | 0.09 | n/a | n/a | n/a | n/a | 30 | 20 | -100% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Novakand Pharma AB (publ), formerly Kancera AB is a Sweden-based company engaged in the biotechnology industry, that develops and sells drug candidates in the field of cancer. The Company focuses on the development of small molecule drug candidates targeting immune cell modulation for the treatment of cardiovascular diseases and cancer. Their key product candidates are KAND567 and KAND145, which are clinical-stage pharmaceutical compounds. These compounds act through the fractalkine system, a biological pathway involved in regulating immune and cancer cell activity. The primary goal of these drug candidates is to reduce inflammation and tissue damage in conditions such as ST-elevation myocardial infarction (STEMI) and ovarian cancer.
Directors
- Erik Nerpin NEC (58)
- Thomas Olin CEO (60)
- Hans Richter CFO (72)
- Martin Norin COO (58)
- Niclas Brynne MGB (60)
- Torbjorn Lundstrom MGB (68)
- Johan Schultz MGB (61)
- Charlotte Edenius IND (63)
- Anders Gabrielsen IND (55)
- Carl-Henrik Heldin IND (65)
- Hakan Mellstedt IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- April 28th, 2010
- Public Since
- February 21st, 2011
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm
- Shares in Issue
- 121,186,228

- Address
- Nanna Svartz Vag 4, SOLNA, 171 65
- Web
- https://novakand.com/
- Phone
- +46 850126080
- Auditors
- Grant Thornton Sweden AB
Similar to NOVKAN
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 13:23 UTC, shares in Novakand Pharma AB are trading at SEK0.23. This share price information is delayed by 15 minutes.
Shares in Novakand Pharma AB last closed at SEK0.23 and the price had moved by -88.01% over the past 365 days. In terms of relative price strength the Novakand Pharma AB share price has underperformed the FTSE Global All Cap Index by -88.94% over the past year.
There is no consensus recommendation for this security.
Find out moreNovakand Pharma AB does not currently pay a dividend.
Novakand Pharma AB does not currently pay a dividend.
Novakand Pharma AB does not currently pay a dividend.
To buy shares in Novakand Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.23, shares in Novakand Pharma AB had a market capitalisation of SEK27.75m.
Here are the trading details for Novakand Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: NOVKAN
Based on an overall assessment of its quality, value and momentum Novakand Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Novakand Pharma AB is SEK1.70. That is 642.36% above the last closing price of SEK0.23.
Analysts covering Novakand Pharma AB currently have a consensus Earnings Per Share (EPS) forecast of SEK2.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novakand Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -83.59%.
As of the last closing price of SEK0.23, shares in Novakand Pharma AB were trading -78.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novakand Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novakand Pharma AB's management team is headed by:
- Erik Nerpin - NEC
- Thomas Olin - CEO
- Hans Richter - CFO
- Martin Norin - COO
- Niclas Brynne - MGB
- Torbjorn Lundstrom - MGB
- Johan Schultz - MGB
- Charlotte Edenius - IND
- Anders Gabrielsen - IND
- Carl-Henrik Heldin - IND
- Hakan Mellstedt - IND